Topiroxostat versus allopurinol in patients with chronic heart failure complicated by hyperuricemia: A prospective, randomized, open-label, blinded-end-point clinical trial
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0261445
Abstract: Background The benefits of xanthine oxidase inhibitors to chronic heart failure (CHF) patients is controversial. We investigated the beneficial effects of a novel xanthine oxidoreductase inhibitor, topiroxostat, in patients with CHF and hyperuricemia (HU), in… read more here.
Keywords: topiroxostat; group; allopurinol; heart failure ... See more keywords
Renoprotective effect of topiroxostat via antioxidant activity in puromycin aminonucleoside nephrosis rats
Sign Up to like & getrecommendations! Published in 2017 at "Physiological Reports"
DOI: 10.14814/phy2.13358
Abstract: Topiroxostat is a novel inhibitor of xanthine oxidase, and is postulated to exert a renoprotective effect. Puromycin aminonucleoside nephrosis (PAN) is a rat model of minimal change nephrotic syndrome. In this study, we examined whether… read more here.
Keywords: puromycin aminonucleoside; aminonucleoside nephrosis; pan rats; topiroxostat ... See more keywords
Comparative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2021 at "International journal of clinical pharmacology and therapeutics"
DOI: 10.5414/cp204108
Abstract: OBJECTIVE We aimed to assess the relative efficacy and safety of topiroxostat at different dosages in hyperuricemic patients with or without gout. MATERIALS AND METHODS A Bayesian network meta-analysis was performed to combine direct and… read more here.
Keywords: efficacy safety; patients without; hyperuricemic patients; topiroxostat ... See more keywords